skin. on us and everyone the joining company to and this Novan for focused you, Thank medical thanks therapies diseases commercializing a developing for dermatology is morning. Andrew that is innovative of building premier
contagiosum. review goal the for gel the FDA our with is the treatment It of date of XXXX. Xth of Berdazimer priority PDUFA January Our molluscum at molluscum, a for under is XX.X% NDA
remaining. We are months less and eight the have in we than cycle review
a of we noteworthy January, had have Since accomplishments. number
Our what ahead. team our and progress, momentum, lies excited our remains about entire
we has of to-date Our NDA most and significant early Novan the which January. are was represents extremely milestone achieved in submitted proud. something This
our date, In issues. was I for goal expected as PDUFA review mentioned, with for known cycle. dates have accepted filing other our review no as milestone potential standard a as March, provided And we well
continue drug commercial anticipation agency potential the in move of toward of approval. We supply with while forward with substance our a preparing dialogue our we
is chemical topical our oxide viral entity. Berdazimer gel XX.X% a nitric sodium, is medication skin new for novel pharmaceutical a releasing Berdazimer ingredient active infections.
Our based clinical from that NDA profile data a evidence Phase molluscum. X of and favorable on for trial with robust B-SIMPLEX is program with demonstrated a safety clinical efficacy our patients
Dermatology data published July from of JAMA trial last were B-SIMPLEX in in year. clinical Our
product and in-office would if patient care So often approved, this need, satisfy time-consuming. cumbersome, are that painful displacing an important procedures largely
if last the impact of diseases left highly is common caregiver received to feedback of Molluscum months. and on less years it most of that the and It the old really prevalent untreated market infection most XX we to them most in worldwide the skin could children, one the XX disease five up of patient. research, than contagious. Through the speaks is skin viral third psyche recent
looking children experiences, at we week, And hopeless, real-world see received you the of here as in actually sense a you give frequently. get we're an We these end the self-confidence. And last feeling a it need to a hope. said, quotes of think at a least their build And parent. from can to bullied, depress, e-mail it sign. a We quite for striking just and that these am e-mail this was sign one I
offerings We million new The or patients in that The many self-administered off-label procedures, in-office freezing, approximately proven administered is and caregiver of options is for current therapy. believe at-home standard six and OTC cutting, US efficacy. blistering care potential results today the large undiagnosed a topical is and lack market cases. have patients in of no prime with annually. million The market the one
patients treatment dermatologist. but XX% molluscum a data, XX% untreated. US but wait-and-see dermatologists of an molluscum treat over XX% of a procedure. Per typically pediatricians of of will with treatment approach. XX% from patients Whereas it's approximately with visit molluscum have XX% go a seek these in-office claims their pediatrician, that's
So, approach follow. standard caregivers seem that care a the There's the that how communities today of become pediatricians patients gel benefit But way Dermatologists view we the what molluscum. first-line we and therapy. XX.X% no wait-and-see would a likely to from potential FDA-approved that believe is future. this lead has is expect We and treatment is berdazimer for a to or not would today.
solutions medical likely the as pharmacy, gel drug next if that would believe Berdazimer could in-office by insurance prescription be new combo at approve be used an if whereby, the could insurance. complement most by be a would believe could FDA by a as So that covered X.X the device dermatologists one across in pediatrician by visits, if approved, prescribed approved, covered treatment months, we multiple We two potential product another. procedure
the there's office. room used one, in drug the both So for device a if prescription, a approved; one, in market,
safe shows specifically gel, and research approved. providers Berdazimer effective healthcare are Our if that and ready for a treatment
who patients As types primary you of high a very today. see high seeing here, across adoption rates HCP months expected very three approval molluscum are -- within are very potential, there's XX the
we're success. So planning for
review with date than less cycle and in currently eight months be the Xth, to is, we're the January review of expecting the again, Our by away. the NDA complete which is goal FDA,
planning to we also respond toward launch. as we're So a requests, potential information FDA
well and healthcare treatment program, we the educate specifically, build and employees. to the customers, best the future employees product access prepare possible we organization. work existing to potential We to about disease deliver to our We look our and providers look So excitement options. awareness want potential commercial as for our among as
technology continue nationally patents with We protect platform globally. and to proprietary our
efforts Now the on remains to these business. available funding dependent the extent of
value. recognize are strategy in patients dermatologist So the go-to-market the eager. value. the our They with the recognize They Their starts opportunity offices.
pediatricians and to expect we them will So look follow.
marketing Berdazimer gel Once our dermatologists, is would out non-derm dermatologists. We the and the we compelling. for market opportunity foundation beyond we playbook to expand prove HCPs look to The expect with have digitally. will mostly to
hand Operating Officer, now our quarter to first an the So update Donofrio, John the I'll of for to provide XXXX. commercial call our business on over Chief
